Plain-English translation of NCT05823532 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Schizophrenia research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
Researchers believe that inflammation in the brain may be making it harder for people with schizophrenia to feel motivated and enjoy activities. This trial tests whether , a medication that blocks inflammation, can improve motivation and pleasure by changing activity in specific brain regions. You would receive either the medication or a placebo (inactive treatment) and complete brain scans and motivation tests to see if the treatment helps.
Current medications for schizophrenia don't work well for treating low motivation and lack of pleasure—symptoms that significantly hurt quality of life. Recent research suggests that brain inflammation may be the underlying cause, so this study is testing whether reducing that inflammation could be a new way to help.
You likely qualify if…
You likely don't qualify if…
You would come to Emory University for eleven visits over several weeks. At your main treatment visit, you'll receive either the medication or placebo through an IV infusion lasting about 2.5 hours, with medical staff monitoring you during and after. Before and after treatment, you'll have blood tests, brain imaging scans (MRI), and complete tasks and questionnaires to measure your motivation and pleasure levels. The entire process helps researchers understand whether this anti-inflammatory treatment can help improve your motivation and quality of life.
AI-generated summary from trial data · Jun 20, 2026 · Not medical advice
United States